HCM News and Press, HUTCHMED (China) Limited From 02/08/22

U.S.-listed Chinese biotech companies are trading lower after the U.S. commerce department added life-sciences company, WuXi Biologics (OTCPK:WXXWY -13.5%) (OTCPK:WXIBF -22.6%), to its “unverified” list for exporters. Notable decliners include I-Mab (IMAB -5.7%) and BeiGene (BGN...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Easter...

Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio’s pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products. Swe...

Hutchmed (China) said the first patient was dosed a phase 1b/2 study in China of HMPL-453 in combination with chemotherapy or anti-PD-1 therapy toripalimab to treat patients with specific advanced or metastatic solid tumors. The first stage of the study is a dose escalation phase to determine...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhi...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and poten...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administra...

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 tha...

Hutchmed (NASDAQ:HCM) has been included by FTSE Russell in the FTSE Global Equity Index Series in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. For...